Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mirror, Mirror: Long-acting Antibiotics Dalbavancin, Oritavancin Emerging With Similar Profiles

Executive Summary

Full results for Durata’s dalbavancin and The Medicine’s Co.’s oritavancin – both lipoglycopeptides – suggest the mode of administration is likely to become a key differentiating factor if the drugs are approved.

You may also be interested in...



Antibiotic Development Incentives Face Critical Test As NDA Reviews Begin

GAIN has encouraged FDA to be flexible on data requirements for antibiotics, according to sponsors.

Antibiotic Development Incentives Face Critical Test As NDA Reviews Begin

Law has encouraged FDA to be flexible on data requirements for antibiotics, according to sponsors.

TMC Bets Dosing Convenience, Field Force Synergies Will Help Oritavancin Prosper

The Medicines Co. held an analyst meeting Oct. 9 in large measure to broadcast the progress it has made diversifying away from its current chief revenue generator, the cardiovascular drug Angiomax. It’s betting that its first foray into antibiotics, the IV-administered drug oritavancin, will best competition because of dosing advantages, efficacy, and the sponsor’s deep expertise in the tumultuous hospital market

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS055629

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel